SA55 nasal spray / Sinovac - LARVOL DELTA

Safety and Intranasal Retention of a Broad-Spectrum Anti-SARS-CoV-2 Monoclonal Antibody SA55 Nasal Spray in Healthy Volunteers: A Phase I Clinical Trial. (PubMed, Pharmaceutics) - "This study demonstrated favorable safety and tolerability of the SA55 nasal spray in healthy volunteers, exhibited satisfactory neutralizing activity against Omicron variants intranasally, and indicated low systemic toxicity risk."

Journal • P1 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

SA55 Novel Coronavirus Broad-spectrum Neutralizing Antibody Nasal Spray in Health People (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Sinovac Life Sciences Co., Ltd.

New P1 trial • Infectious Disease • Novel Coronavirus Disease